DSpace Repository
Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV
- DSpace Home
- →
- Research Publications
- →
- School of Medicine
- →
- View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Siika, Abraham | |
| dc.date.accessioned | 2022-04-20T09:49:03Z | |
| dc.date.available | 2022-04-20T09:49:03Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://www.nejm.org/doi/full/10.1056/NEJMoa2101609 | |
| dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/6264 | |
| dc.description.abstract | The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | The New England Journal of Medicine | en_US |
| dc.subject | HIV | en_US |
| dc.title | Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV | en_US |
| dc.type | Article | en_US |
